Mitomycin is an older drug that has been well studied in prostate cancer. It has some anti-cancer effect but it is not substantial.It does better in combinations.Based on their previous clinical experience with VE, Logothetis et al have recently reported that the addition of mitomycin-C to the VE regimen substantially improves efficacy. The rate of PSA reduction among 31 patients with initially elevated PSA was 66% and the duration of response was 2 months. In addition, 7% of 28 patients with osseous disease experienced improved bone scans.
Mitomycin in prostate cancer not recommended
Source: PharmacoEconomics and Outcomes News, Volume 1, Number 273, 2000 , pp. 10-10(1)
Amato R, Logothetis C, Sella A, et al: Preliminary results of a phase II trial of estramustine (Emcyt), vinblastine (VLB) and mitomycin-C (MMC) for patients with progressive androgen independent prostate carcinoma (AIPCa) (abstract 1213). Proc Am Assoc Cancer Res 34:203, 1993.